These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10502355)

  • 1. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
    Foulon CF; Bigner DD; Zalutsky MR
    Bioconjug Chem; 1999; 10(5):867-76. PubMed ID: 10502355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.
    Reist CJ; Bigner DD; Zalutsky MR
    Clin Cancer Res; 1998 Oct; 4(10):2495-502. PubMed ID: 9796983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.
    Karacay H; Sharkey RM; Govindan SV; McBride WJ; Goldenberg DM; Hansen HJ; Griffiths GL
    Bioconjug Chem; 1997; 8(4):585-94. PubMed ID: 9258459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.
    Zalutsky MR; Archer GE; Garg PK; Batra SK; Bigner DD
    Nucl Med Biol; 1996 May; 23(4):449-58. PubMed ID: 8832699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation, characterization, and biological evaluation of a streptavidin-chimeric t84.66 conjugate for antibody pretargeting.
    Jia F; Shelton TD; Lewis MR
    Cancer Biother Radiopharm; 2007 Oct; 22(5):654-64. PubMed ID: 17979568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased streptavidin uptake in tumors pretargeted with biotinylated antibody using a conjugate of streptavidin-fab fragment.
    Yao Z; Zhang M; Sakahara H; Saga T; Kobayashi H; Nakamoto Y; Toyama S; Konishi J
    Nucl Med Biol; 1998 Aug; 25(6):557-60. PubMed ID: 9751423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
    Lee Y; Bullard DE; Humphrey PA; Colapinto EV; Friedman HS; Zalutsky MR; Coleman RE; Bigner DD
    Cancer Res; 1988 May; 48(10):2904-10. PubMed ID: 2452014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin.
    Wilbur DS; Hamlin DK; Meyer DL; Mallett RW; Quinn J; Vessella RL; Press OW
    Bioconjug Chem; 2002; 13(3):611-20. PubMed ID: 12009953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Yordanov AT; Hens M; Pegram C; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2007 Feb; 34(2):173-83. PubMed ID: 17307125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody.
    Hauck ML; Zalutsky MR
    Clin Cancer Res; 1998 Sep; 4(9):2071-7. PubMed ID: 9748121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
    Schuster JM; Garg PK; Bigner DD; Zalutsky MR
    Cancer Res; 1991 Aug; 51(16):4164-9. PubMed ID: 1714341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
    Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
    Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
    J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
    Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
    Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.
    Lee YS; Bullard DE; Zalutsky MR; Coleman RE; Wikstrand CJ; Friedman HS; Colapinto EV; Bigner DD
    Cancer Res; 1988 Feb; 48(3):559-66. PubMed ID: 2446747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin.
    He X; Archer GE; Wikstrand CJ; Morrison SL; Zalutsky MR; Bigner DD; Batra SK
    J Neuroimmunol; 1994 Jul; 52(2):127-37. PubMed ID: 7518471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.
    Zalutsky MR; Noska MA; Colapinto EV; Garg PK; Bigner DD
    Cancer Res; 1989 Oct; 49(20):5543-9. PubMed ID: 2477144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
    Goodwin DA; Meares CF; Osen M
    J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
    Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
    Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
    Bigner DD; Brown M; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Bigner SH; Zhao XG; Wikstrand CJ; Pegram CN
    J Neurooncol; 1995; 24(1):109-22. PubMed ID: 8523067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.